Chemoprevention: A primary cancer prevention strategy

Seminars in Oncology Nursing

Volumn 21, Issue 4, 2005, Pages 243-251

  Smith, Judith J ^a,c   Tully, Patricia ^b   Padberg, Rose Mary ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27744575798     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2005.06.009     Document Type: Article

References (47)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. S.M. Lippman, B. Levin, D.E. Brenner Cancer prevention and the American Society of Clinical Oncology J Clin Oncol 22 2004 3848 3851
3. H. Vaino, F. Bianchini Prevention of disease with pharmaceuticals Pharmacol Toxicol 88 2001 111 118
4. M.B. Sporn, N.M. Dunlop, D.L. Newton Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc 35 1976 1332 1338
5. L.W. Wattenberg An overview of chemoprevention Current status and future prospects Proc Soc Exp Biol Med 216 1997 133 411
6. S.M. Lippman, S.E. Benner, W.K. Hong The chemoprevention of cancer P. Greenwald B.S. Kramer D.L. Weed Cancer prevention and control 1995 Marcel Dekker New York, NY 329 352
7. S.M. Lippman, S.E. Benner, W.K. Hong Chemoprevention Strategies for the control of cancer Cancer 72 1993 984 990
8. S.M. Lippman, S.E. Benner, W.K. Hong Cancer chemoprevention J Clin Oncol 12 1994 851 873
9. A.S. Tsao, E.S. Kim, W.K. Hong Chemoprevention of cancer CA Cancer J Clin 54 2004 150 180
10. P. Greenwald, G. Kelloff, C. Burch-Whitman Chemoprevention CA Cancer J Clin 45 1995 31 49
11. G.J. Kelloff, C.C. Sigman, P. Greenwald Cancer chemoprevention Progress and promise Eur J Cancer 35 1999 2031 2038
12. W.K. Hong, S.M. Lippman Cancer chemoprevention J Natl Cancer Inst 17 1995 49 53
13. D.K. Swan, B. Ford Chemoprevention of cancer Review of the literature Oncol Nurs Forum 24 1997 719 727
14. F.L. Meyskens, P. Tully Principles of cancer prevention Semin Oncol Nurs 21 2005 229 235
15. P. Greenwald Cancer prevention clinical trials J Clin Oncol 20 suppl 2002 14S 22S
16. G.E. Goodman The clinical evaluation of cancer chemoprevention agents Defining and contrasting phase I, II, and III objectives Cancer Res 52 suppl 1992 2752s 2757s
17. S.M. Sharp, R.D. Pentz Issues, both ethical and practical, in the development and conduct of chemoprevention trials Curr Probl Cancer 28 2004 186 200
18. G.S. Omenn Chest. Human lung cancer chemoprevention strategies: Parker B. Francis lecture Chest 125 suppl 5 2004 123S 127S
19. D.K. Singh, S.M. Lippman Cancer chemoprevention part 1 Retinoids and carotenoids and other classic antioxidants Oncology 12 1998 1643 1660
20. M.M. Manson, A. Gescher, E.A. Hudson Blocking and suppressing mechanisms of chemoprevention by dietary constituents Toxicol Lett 112-113 2000 499 505
21. E.T. Hawk, S.M. Lippman Primary cancer prevention trials Hematol Oncol Clin North Am 14 2000 809 831
22. G.J. Kelloff, E.T. Hawk, J.A. Crowell Strategies for identification and clinical evaluation of promising chemopreventive agents Oncology 10 1996 147 188
23. V.G. De Gruttola, P. Clax, D.L. DeMets Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop Control Clin Trials 22 2001 485 502
24. A.L. Sabichi, M.F. Demierre, E.T. Hawk Frontiers in cancer research Cancer Res 63 2003 5649 5655
25. R. Frank, R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580
26. F.L. Meyskens Biomarker intermediate endpoints and cancer prevention J Natl Cancer Inst Monogr 13 1992 177 181
27. E.T. Hawk, J.L. Viner, J. Lawrence Biomarkers as surrogates for cancer development Curr Oncol Rep 2 2000 242 250
28. B. Fisher, J.P. Costantino, D.L. Wickerham Tamoxifen for prevention of breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
29. US Department of Health and Human Services (DHHS). National Institutes of Health (NIH). STAR Home Page; STAR. Available at http://www.cancer.gov/ clinicaltrials/digestpage/STAR. (accessed March 30, 2005).
30. J.A. Cauley, L. Norton, M.E. Lippman Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 65 2001 125 134
31. I.M. Thompson, P.J. Goodman, C.M. Tangen The influences of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
32. E.A. Klein, I.M. Thompson, S.M. Lippman SELECT The next prostate cancer prevention trial J Urol 166 2001 1311 1315
33. L.C. Clark, G.F. Combs, B.W. Turnbull Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin JAMA 276 1996 1957 1963
34. The Aplpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers N Engl J Med 330 1994 1029 1035
35. G.S. Oemnn, G.E. Goodman, M.D. Thornquist Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 1996 1150 1155
36. G.E. Goodman, M.D. Thornquist, J. Balmes The Beta-Carotene and Retinol Efficacy Trial Incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements J Natl Cancer Inst 96 2004 1743 1750
37. P. Greenwald β-carotene and lung cancer A lesson for future chemoprevention investigations? J Natl Cancer Inst 95 2003 E1
38. W.K. Hong, S.M. Lippman, L. Itri Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck N Engl J Med 323 1990 795 801
39. M.E. Reid, A.J. Dufffield-Lillico, L. Garland Selenium supplementation and lung cancer incidence An update of the Nutritional Prevention of Cancer Trial Cancer Epidemiol Biomarkers Prev 11 2002 1285 1291
40. A.J. Duffield-Lillico, M.E. Reid, B.W. Turnbull Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial A summary report of the Nutritional Prevention of Cancer Trial Cancer Epidemiol Biomarkers Prev 11 2002 630 639
41. P.R. Taylor, P. Greenwald Nutritional interventions in cancer prevention J Clin Oncol 23 2005 333 345
42. G. Steinbach, P.M. Lynch, R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
43. S.D. Solomon, J.V. McMurray, M.A. Pfeffer Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
44. US Department of Health and Human Services (DHHS). National Institutes of Health (NIH). Adenoma Prevention Trial Home Page. Available at: http://www.cancer.gov/newscenter/pressreleases/APCtrialCOX2QandA (accessed March 30, 2005).
45. R.S. Bresalier, R.S. Sandler, H. Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
46. Department of Health and Human Services (DHHS). Food and Drug Administration (FDA). Available at: http://www.fda.gov/oc/advisory/accalendar/ 2005/cder12532ddd0216171805.html (accessed March 30, 2005).
47. FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available at: http://www.fda.gov/cder/drug/ advisory/COX2.htm (accessed Oct 3, 2005).